Top Markets
#1 GEKKO GEKKO +50.71%
#2 ADO Protocol ADO Protocol +38.43%
#3 Helium Helium +32.25%
#4 Pons Pons +29.76%
#5 TENDIES TENDIES +22.22%
#6 CZ'S Dog CZ'S Dog +20.99%
#7 Giggle Fund Giggle Fund +20.95%
#8 龙虾 (Lobster) 龙虾 (Lobster) +19.51%
#9 Main Street Yield Main Street Yield +17.48%
#10 o1.exchange o1.exchange +17.25%
Coin of the day
GEKKO GEKKO
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Harrow Health, Inc. 8.625% Senior Notes due 2026 Harrow Health, Inc. 8.625% Senior Notes due 2026

Harrow Health, Inc. 8.625% Senior Notes due 2026

HROWL
Rang in aandelen #8091
Harrow, Inc. is a pharmaceutical company that specializes in the development,... Harrow, Inc. is a pharmaceutical company that specializes in the development, production, and distribution of innovative medications. Its business activities are primarily divided into two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding division notably encompasses the operations of the ImprimisRx business. Co-founded by Mark L. Baum and Robert J. Kammer in January 2006, the firm maintains its corporate headquarters in Nashville, Tennessee.
Aandeelprijs
$25.61
Laatst gesynchroniseerd: 2025-10-10
Marktkapitalisatie
$1.37B
Verandering (1 dag)
0.20%
Verandering (1 jaar)
1.55%
Land
US
Handel Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)

Categorie

Healthcare
Winst voor Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Harrow Health, Inc. 8.625% Senior Notes due 2026 bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Harrow Health, Inc. 8.625% Senior Notes due 2026 van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Sino Biopharmaceutical Limited Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited
1177.HK
$992.42M -
HK
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT